Table 4.
Frequencies of the individual complications mentioned, per cohort. Percentages between brackets.
| Cohort A n = 417 |
Cohort B n = 239 |
p-Value | |
|---|---|---|---|
| Short-term complications | |||
| Fatigue | 141 (33.8) | 103 (43.1) | 0.2 |
| Pain | 80 (19.2) | 72 (30.1) | 0.02 |
| Infection (NOS) | 70 (16.8) | 54 (22.6) | 0.3 |
| Wound infection | 66 (15.8) | 71 (29.7) | 0.001 |
| Bleeding | 51 (12.2) | 74 (31.0) | 0.03 |
| Thrombosis | 39 (9.4) | 33 (13.8) | 0.08 |
| Pneumonia | 36 (8.6) | 35 (14.6) | 0.23 |
| Urinary tract infection | 26 (6.2) | 35 (14.6) | <0.0001 |
| Death | 21 (5.0) | 32 (13.4) | 0.57 |
| Damage to other organs | 3 (0.7) | 1 (0.4) | 0.93 |
| Neuropathy/neurapraxia | 3 (0.7) | 6 (2.5) | 0.11 |
| Cardiovascular complications | 2 (0.5) | 2 (0.8) | 0.66 |
| Testicular complaints a,b | 0 | 3 (1.3) | 0.8 |
| Long-term complications | |||
| ESKD | 66 (15.8) | 35 (14.6) | 0.87 |
| Chronic pain | 11 (2.6) | 6 (2.5) | 0.74 |
| Hypertension | 11 (2.6) | 13 (5.4) | 0.13 |
| Incisional hernia | 4 (1.0) | 4 (1.7) | <0.0001 |
| Medication (NSAIDs, AB) | 1 (0.2) | 3 (1.3) | 0.18 |
NOS: not otherwise specified; ESKD: end-stage kidney disease; NSAIDs: nonsteroidal anti-inflammatory drugs: AB: antibiotics; NA: not applicable. a Since testicular complaints are a relevant complication only in male donors, the relevant percentage is 2.7% (3 out of 110 males in Cohort B), instead of 1.3% for the whole group of 226 donors. b Because none of the Cohort A donors reported this complication, a p-value could not be computed using the generalized linear model.